Sage Therapeutics' Experimental Drug for Huntington's Disease Fails Mid-Stage Trial
The drug, dalzanemdor, did not significantly improve cognitive function in patients compared to placebo after 84 days, failing to meet the main goal
Bengaluru: Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on Wednesday.
The drug, dalzanemdor, did not significantly improve cognitive function in patients compared to placebo after 84 days, failing to meet the main goal of the study.
Also Read: Sage Therapeutics reshuffles leadership, cuts 165 jobs to focus on postpartum depression drug launch
The drug also failed to achieve "statistical significance" in secondary goals of the study, Sage said.
Huntington's disease is an inherited disorder that causes nerve cells in parts of the brain to gradually break down and die.
Also Read: Biogen, Sage Therapeutics get USFDA nod for Zurzuvae for postpartum depression in women
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.